Biopharmaceutical News and Research

RSS

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Fluidic Sciences and Sphere Bio 20 Jul 2020

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities.

16 Jul 2020

MD Anderson and Sanofi collaborate to accelerate development of innovative cancer therapies

The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.

14 Jul 2020

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

BIA Separations signs new distribution agreements with two companies in Asia

BIA Separations, a leading bio-chromatography development and manufacturing company, today announced it has signed agreements with Bioscience companies, GeneX India Biosciences Pvt. Ltd. and IT Technologies Pte. Ltd.

9 Jul 2020

Study sheds new light on protein movement

Many of the most promising medicines under development are proteins, often antibodies, to help patients fight disease. These proteins must be purified as part of the manufacturing process - a task that can be tricky and result in costly waste.

8 Jul 2020

Rigaku Analytical Devices to present during Thai Industrial Pharmacist Association (TIPA) webinar

Rigaku Analytical Devices, the market leader in handheld 1064nm Raman technology, will present its solution for raw material identification during a webinar hosted by the Thai Industrial Pharmacist Association on July 16, 2020 at 9:30 am ICT / 8:30 pm EDT.

From Rigaku Analytical Devices 6 Jul 2020

New agreements to increase access to cancer medicines and save countless lives

The American Cancer Society and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.

29 Jun 2020

USask researchers receive $900,000 to help strengthen Canada's rapid response to COVID-19

The Canadian Institutes of Health Research has awarded three University of Saskatchewan research teams a total of $900,000 to help strengthen Canada's rapid response to the COVID-19 pandemic which had killed more than 450,000 people worldwide.

25 Jun 2020

New methods may contribute to future structure-based drug design

Many pharmaceuticals work by targeting what are known as "G-protein-coupled receptors". In a new study, scientists from Uppsala University describe how they have been able to predict how special molecules that can be used in new immunotherapy against cancer bind to these receptors.

24 Jun 2020

Members of Vivli announce commitment to share COVID-19 trial data

Members of Vivli, the Center for Clinical Research Data, announce today their commitment to share their COVID-19 trials through Vivli.

23 Jun 2020

Jubilant Therapeutics announces preclinical data of dual LSD1 and HDAC6 inhibitor at AACR 2020

Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data of dual LSD1 and HDAC6 inhibitor JBI-802, will be presented in a poster session at the American Association for Cancer Research 2020 Virtual Annual Meeting II.

23 Jun 2020

UQ superbug drug discoveries will be fast-tracked under international research deal

Antibiotics discovered at The University of Queensland will be fast-tracked under an US$11 million international research deal.

22 Jun 2020

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Jun 2020

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Critical Path Institute announced today that its Transplant Therapeutics Consortium has received a positive response to its Letter of Intent from the U.S. Food and Drug Administration detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program.

17 Jun 2020

Antisense Therapeutics: Poster presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

Antisense Therapeutics, an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association Virtual 2020 Conference website.

15 Jun 2020

Corrona Psoriasis Registry to present studies at AAD Virtual Meeting Experience

The Corrona® Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation, NPF, and Corrona, LLC, the leading sponsor of registries in immune-mediated diseases, announces that studies from the registry will be presented at the American Academy of Dermatology Virtual Meeting Experience taking place June 12-14, 2020.

12 Jun 2020

Using nanotheranostics approach to treat cancer

The concept of theranostics revolves around the stratification of patients into specific groups based on their response to different treatments and their disease risks.

10 Jun 2020

Study reveals new strategy to tackle cancer

A study led by the Institut de Neurociències describes a new strategy to tackle cancer, based on inducing a potent stress in tumor causing cell destruction by autophagy.

9 Jun 2020